动态评估肝纤维化可预测丙肝治愈后肝癌风险
研究纳入522例经干扰素治疗获得持续病毒学应答(SVR)的慢性丙肝患者,每年根据实验室值重新计算FIB-4指数并评估肝癌发生。结果显示SVR后轻度肝纤维化(FIB-4<1.45)患者比例逐年增加,晚期肝纤维化(FIB-4≥3.25)比例下降,但基于更新后FIB-4的肝癌发生率保持稳定;FIB-4降至<1.45者无肝癌发生。
要点
- SVR后每年动态计算FIB-4可维持对肝癌风险的预测能力。
- FIB-4降至<1.45者即使从晚期纤维化回归也未发生肝癌。
- 动态FIB-4评估有助于优化SVR后肝癌监测策略。
核心结论
- SVR后动态重算FIB-4指数仍能预测肝癌风险,FIB-4<1.45者未发生肝癌。
研究设计与样本
- 回顾性队列研究,纳入522例经干扰素治疗获得SVR的慢性丙肝患者,每年重算FIB-4并评估肝癌发生。
主要发现
- SVR后FIB-4<1.45者比例逐年增加,FIB-4≥3.25者比例逐年下降。
- 基于年度更新FIB-4的肝癌发生率在SVR时与后续年度间保持恒定。
- FIB-4降至<1.45的患者即使由晚期纤维化回归,也未发生肝癌。
关键数值与推荐
- FIB-4<1.45定义为轻度肝纤维化,FIB-4≥3.25定义为晚期肝纤维化。
临床怎么用
- SVR后应每年重算FIB-4以动态评估肝癌风险。
- FIB-4降至<1.45者可考虑减少肝癌监测频率。
局限性
- 需进一步研究确认上述发现,可能减少需监测的患者数量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Liver fibrosis is an important risk factor for the development of hepatocellular carcinoma (HCC) after sustained virologic response (SVR) in patients with persistent hepatitis C virus (HCV) infection. However, as the degree of liver fibrosis changes following the eradication of HCV after SVR, it is unclear whether the prediction of HCC development based on liver fibrosis at baseline remains valid. METHODS: In 522 patients who achieved SVR by interferon-based anti-HCV therapy, the Fibrosis-4 Index for Liver Fibrosis (FIB-4 index) was updated annually by recalculation based on laboratory values after SVR. The incidence of HCC was reassessed annually based on the updated FIB-4 index. RESULTS: The percentage of patients with mild liver fibrosis (FIB-4 index <1.45) increased annually after SVR, whereas the percentage of patients with advanced liver fibrosis (FIB-4 index ≥3.25) decreased. The incidences of HCC based on the FIB-4 index remained constant between the time of SVR and subsequent annual updates. No patients developed HCC after SVR if the FIB-4 index decreased to <1.45. CONCLUSIONS: The FIB-4 index retained its predictive ability for the risk of HCC when recalculated after SVR, despite the decrease in patients with high FIB-4 index values. Dynamic assessment of the FIB-4 index can be useful in the surveillance of HCC after SVR. Patients with a FIB-4 index <1.45 did not develop HCC even by the regression from advanced fibrosis after SVR. Further studies will be necessary to confirm these findings, which may result in a decrease in the number of patients in whom surveillance is required.
引用
- Toyoda H, Tada T, Yasuda S, et al. Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Who Achieved Sustained Virologic Response. Clin Infect Dis. 2020. PMID: 31056696. doi:10.1093/cid/ciz359
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。